GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.In our ongoing clinical development program, we are evaluating the impact of voxelotor on abnormal polymerization of deoxy-hemoglobin, the underlying mechanism of red blood cell sickling. We believe that this mechanism is potentially relevant for all patients with SCD and have designed a clinical program targeted at the treatment of SCD patients across all ages and genotypes.
|Bank Name||Global Blood Therapeutics, Inc.|
|CEO||Dr. Ted W. Love|